Structure Therapeutics (GPCR) has unwound sharply after its explosive run on positive aleniglipron obesity‑pill data, and price is now sitting in my daily buying scope inside the broader up‑channel.
I’m looking for the GLP‑1 narrative and upcoming Phase 3 pivot to support a swing back toward the 85–95 area, where I’ve mapped successive upside targets aligned with prior supply and fib levels, with invalidation on a clean daily close below my lowest buy zone.
If you’d like to learn more about how I trade setups like this, you can find more details about me and my work in my profile bio.